Engineered immune cells take on childhood cancer
NCT ID NCT06865664
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-phase trial tests a new treatment for children and young adults (ages 3–39) with rhabdomyosarcoma that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better target and attack cancer cells. Participants first receive chemotherapy to prepare their body, then a single infusion of the modified cells, and are closely monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FGFR4-CAR T cells (a type of modified immune cell)
What this could lead to
If this works, it could point toward a new treatment option for children and young adults with hard-to-treat rhabdomyosarcoma.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, so it may not show clear benefit. There are also risks of serious side effects from the modified cells and chemotherapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.